Lumos Diagnostics Holdings (ASX:LDX) said it will start receiving Medicare reimbursement for its FebriDx rapid diagnostic test designed to distinguish bacterial from viral respiratory infections in two US regions, according to a Thursday filing with the Australian bourse.
Effective this month, the test has been included in the Medicare fee schedule in the Palmetto and Novitas regions at a rate of $41.38 per test, the filing said.
The test is reimbursable in both moderately complex and clinical laboratory improvement amendments waived settings, the company said.
Shares of the company rose about 14% in recent Thursday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。